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Raised blood pressure (BP) was the biggest contributor to the global burden of disease
in 2017, with lack of awareness and adequate control of BP identified as the main driv-
ers of this disease burden. In 2017, an opportunistic BP screening and awareness cam-
paign called May Measurement Month (MMM) in the UK and Republic of Ireland (RoI)
highlighted that levels of undiagnosed hypertension and uncontrolled hypertension in
the community screened were approximately 23% and 40%, respectively. MMM18 was
undertaken to further the campaign’s efforts to increase awareness and create an evi-
dence base of population risk associated with high BP. MMM18 BP screenings were con-
ducted in the community at places of worship, supermarkets, GP surgeries, workpla-
ces, community pharmacies, gyms, and various other public places. A total of 5000
volunteers, aged 47.3 (617.2) years, 60% female were screened. Of all 5000 individu-
als screened, 1716 (34.3%) were hypertensive, of which only 51.3% were aware of
their condition, 42.8% on antihypertensive treatment, and only 51.5% of those on med-
ication controlled to target BP of <140/90mmHg. Furthermore, obese, overweight,
and underweight participants all had significantly higher BP values compared to indi-
viduals with a healthy body mass index (BMI). The 2018 MMM campaign in the UK and
the RoI confirmed approximately one in three adults were hypertensive, with more
than half having uncontrolled BP. In addition, these findings show that people with low
BMI are at risk of having high BP. Finally, with only one in two people aware of their
high BP, awareness remains a significant public health concern.
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Introduction
Hypertension affects more than 1 billion people world-
wide, with numbers predicted to reach over 1.5 billion by
2025.1 With raised blood pressure (BP) as the biggest con-
tributor to the global burden of disease in 2017,2 lack of
awareness and adequate control of BP to national targets
are identified as the main drivers of this disease burden.
Globally, it has been shown that less than half of those with
hypertension are aware they have the condition.3 In the UK
and Republic of Ireland (RoI), BP awareness and surveil-
lance systems are generally implemented through their re-
spective health care services and national clinical
databases. Data from 2011 reported a prevalence of hyper-
tension in England of 30%, with only 37% of those hyperten-
sive patients controlled to target.4,5 Furthermore, data
from 2014 highlighted that an age-standardized prevalence
of raised BP (140 or 90mmHg) was 15.2% in the UK and
27.9% in the RoI.6 However, the extent of the problem in
thewider community, especially thosewho do not regularly
access health services has yet to be established. In 2017,
the first May Measurement Month (MMM) BP screening cam-
paign was conducted in the UK and the RoI. A total of 7695
participants were screenedwith 40.3% of participants iden-
tified as having hypertension and only 21.9% reported as
taking regular antihypertensive medications. Importantly,
the proportion of participants with hypertension and not
receiving treatment was recorded as 23.4% and of those hy-
pertensive participants receiving treatment, only 59.5%
were deemed to be controlled (BP <140/90mmHg).7
These data highlighted the inappropriately high levels of
undiagnosed hypertension in the community and low levels
of BP control in hypertensive patients.
As a result of these findings, members of the British and
Irish Hypertension Society (BIHS) and International Society
of Hypertension (ISH) coordinated screenings across the UK
and the RoI to further the campaign’s efforts to increase
awareness and create an evidence base of the extent of
population risk associatedwith high BP.
Methods
Over the month of May 2018, opportunistic screening sites
were set up to measure and increase awareness of BP.
Screenings were conducted out in the community at pla-
ces of worship, supermarkets, GP surgeries, workplaces,
community pharmacies, gyms, and various other public
places. Investigator-led training days for partners and
those taking part in BP screening were conducted prior to
screening events. Omron devices were provided to na-
tional partners that did not possess a validated BP system.
In Wales, local funding from Cardiff Metropolitan
University and Hirumed Ltd was used for marketing and
campaign promotion purposes. In England, local funding
was provided by the Academy of Medical sciences INSPIRE
funding for marketing and logistics purposes. Celebrity
and government public health endorsements via social
media, national webpages, and newspaper articles were
used to promote the campaign nationally. As per guide-
lines, only validated BP monitors were used and measure-
ments were conducted in the seated position with 2nd
and 3rd measurements used for analysis. Hypertension
was defined as systolic BP  140 mmHg or diastolic BP 
90mmHg or on treatment for hypertension. In addition to
the BP measurements, anonymized questionnaire-based
information relating to BP (demographic, lifestyle, and
environmental) were collected. Recorded measures of
weight and height were measured or self-reported and
body mass index (BMI) calculated. Body mass index cate-
gories were represented as: underweight: <18.5 kg/m2;
healthy weight: 18.5–24.9 kg/m2; overweight: 25–
29.9 kg/m2 and obese: >30 kg/m2. Data were collected
using the MMM app, spreadsheets, or hard copy. Data
were cleaned locally by the BIHS or MMM lead in Wales. All
UK and RoI data were analysed centrally by the MMM proj-
ect team, where multiple imputation was performed to
obtain the mean of readings 2 and 3, where data were
missing, based on the global data. Please refer to the
methods section in MMM 2018 global paper for more in-
depth information on collection, imputation, and de-
tailed analyses.8
Results
Following the screening of 5000 volunteers with a mean
age of 47.3 (617.2) years and a male: female distribution
of 40:60 in the UK and the RoI, 1716 (34.3%) were hyper-
tensive, of whom 42.8% were on antihypertensive treat-
ment and only 51.5% of those on medication controlled to
target BP of <140/90mmHg. Moreover, in all volunteers,
only 22.1% were within the BP target range or controlled
to target and of those not taking antihypertensive medi-
cation, 981 (23.0%) were found to have hypertension.
Interestingly, these data show that only 51.3% of people
with hypertension were aware of their condition.
Data were collected in a wide range of ethnic groups:
6.3% South Asian, 2.0% East Asian, 2.3% South East Asian,
4.6% Black, 77.6% White, and 0.9% Arabic. Increased sys-
tolic BP was associated with increased age, however, dia-
stolic pressure increased between the ages of 18 and
49 years, before decreasing after approximately 50years
(Supplementarymaterial online, Figure S1).
A curvilinear relationship was observed between both
systolic and diastolic BP and BMI. Obese, overweight, and
underweight participants all had significantly higher BP
values compared to BP of individuals with a normal BMI
[systolic BP: 7, 4, and 3mmHg higher than BPof normal BMI
group, respectively; and diastolic BP: 5, 3, and 4mmHg
higher than BP of normal BMI group, respectively
(Supplementarymaterial online, Figure S2)].
Discussion
These MMM18 data from the UK and the RoI highlight the
fact that awareness of high BP remains an issue in the com-
munity, with just half of people with hypertension aware of
Analysis of blood pressure screening results from the UK and the RoI H133
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartjsupp/article/22/Supplem
ent_H
/H
132/5898731 by U
niversity of W
arw
ick user on 29 Septem
ber 2020
their condition. In contrast to the previous evaluations,
this campaign identified a third of people as hypertensive
compared to the 40.3% identified in the UK and the RoI
MMM2017 dataset. These differences may highlight bias in
self-selection or a ‘healthy effect’ in terms of selection in
the MMM18 data, masking the true proportion of those with
hypertension in the community. Importantly, only 4 of 10 of
those identified as hypertensive reported taking antihyper-
tensive treatment, with only half of those on medication
controlled to a target (systolic BP<140mmHg and diastolic
BP <90 mmHg). Finally, these data highlight the important
public health message that people who are underweight
appear to have higher BP than those with a healthy weight
and similar to those who are overweight and obese, al-
though this relationship was not found in our data from
2017. These associations emphasize the major BP-related
risk linking body weight and cardiovascular risk, which
requires further public health attention.
Interestingly, these data illustrate that the proportion of
hypertensive individuals identified through the MMM17 and
2018 datasets remain higher than the reported high BP
prevalence data in the UK and the RoI (15.2% and 27.9%, re-
spectively) from 2014. Similar to UK and the RoI data pre-
sented in MMM17, systolic BP increased with age with
diastolic pressure increasing before decreasing after ap-
proximately 50 years.
The present data add to the growing evidence that
awareness of BP is a significant public health issue within
the UK and the RoI, and that a pragmatic, opportunistic, in-
expensive, convenience sampling method of screening can
help identify people at risk. More concerted efforts are
therefore needed by national public health and policy-
makers to promotemore systematic screening initiatives in
the future, with the aim of minimizing population risk and
national economic burden of diseases associated with hy-
pertension. Whilst helpful to understand the degree of BP
associated problems in those who regularly attend their GP
practice or occupational health services, traditional data
in relation to prevalence of hypertension, undiagnosed hy-
pertension, and awareness may not be directly related to
the extent of the problem in the wider community.
Through the greater involvement of partners from differ-
ent sectors and the inexpensive, convenience sampling na-
ture of the campaign, MMM was able to reach communities
that otherwise may not have had access to measuring and
knowing their BP.
Supplementary material
Supplementary material is available at European Heart
Journal Supplements online.
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